Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Top Headlines

Pharmaceutical Business Review

AstraZeneca elects to return AZD9412 drug rights to Synairgen AstraZeneca has opted to return rights on drug AZD9412 (inhaled interferon beta) to Synairgen, which did not meet the pharma giant's predefined criteria for progression in a trial. Contract Research & Services > Clinical Trials > News
Takeda, Harrington to advance development of rare disease therapeutics Takeda Pharmaceutical has entered into a multi-year partnership with Harrington Discovery Institute at University Hospitals in Cleveland, Ohio to advance the development of rare disease rherapeutics.
Drug Research > Drug Discovery & Development > News FDA grants Pfizer’s Lorlatinib breakthrough designation for NSCLC The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pfizer’s lorlatinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), who were earlier treated with one or more ALK inhibitors.
Production & Manufacturing > Process & Production > News AstraZeneca elects to return AZD9412 drug rights to Synairgen By PBR Staff Writer
AstraZeneca has opted to return rights on drug AZD9412 (inhaled interferon beta) to Synairgen, which did not meet the pharma giant's predefined criteria for progression in a trial.
Contract Research & Services > Clinical Trials > News
Shire wins EC conditional approval for Natpar to treat hypoparathyroidism By PBR Staff Writer
Shire has secured conditional marketing approval from the European Commission (EC) for its Natpar (rhPTH[1-84]) to treat patients with chronic hypoparathyroidism.
Regulatory Affairs > News Teva launches generic Vytorin tablets in US Teva Pharmaceutical Industries has launched the generic Vytorin (ezetimibe and simvastatin) tablets in the US.
Drug Research > Drug Delivery > News Gates Foundation leads $45.5m round for biotechnology firm Arsanis Clinical-stage biopharmaceutical firm Arsanis has secured $45.5m in a Series D financing round led by the Bill & Melinda Gates Foundation.
Drug Research > Drug Discovery & Development > News

Latest News and Insight by Sector

Production & Manufacturing

FDA grants Pfizer’s Lorlatinib breakthrough designation for NSCLC
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pfizer’s lorlatinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), who were earlier treated with one or more ALK inhibitors.
Production & Manufacturing > Process & Production > News
uniQure’s gene therapy for severe hemophilia B gets PRIME designation in Europe
uniQure’s AMT-060 investigational gene therapy in patients with severe hemophilia B, has been granted PRIME designation by the European Medicines Agency (EMA).
Production & Manufacturing > Process & Production > News

Drug Research

Takeda, Harrington to advance development of rare disease therapeutics
Takeda Pharmaceutical has entered into a multi-year partnership with Harrington Discovery Institute at University Hospitals in Cleveland, Ohio to advance the development of rare disease rherapeutics.
Drug Research > Drug Discovery & Development > News
Teva launches generic Vytorin tablets in US
Teva Pharmaceutical Industries has launched the generic Vytorin (ezetimibe and simvastatin) tablets in the US.
Drug Research > Drug Delivery > News

Inward Investment

New WuXi Life Science to acquire WuXi PharmaTech for $3.3bn
Shanghai-based WuXi PharmaTech has entered into a merger agreement with New WuXi Life Science and its wholly owned subsidiary WuXi Merger, worth a total cash consideration of $3.3bn.
Inward Investment > News
PPF Group acquires minority stake in Cytune Pharma
By PBR Staff Writer
PPF Group, in cooperation with SOTIO has completed acquisition of minority stake in French biotechnology firm Cytune Pharma.
Inward Investment > News

Packaging

Catalent completes acquisition of Australia's Pharmapak
By PBR Staff Writer
US-based Catalent Pharma Solutions has strengthened its ability to provide integrated solutions to customers with the acquisition of Pharmapak Technologies, an Australian pharmaceutical packaging business.
Production & Manufacturing > OTC > News
MP Global Products introduces foam-free packaging for shipment of temperature sensitive pharmaceuticals
MP Global Thermal Packaging Products insulated protective mailers and box liners are specifically designed for temperature control and protection of mail order shipments of temperature sensitive pharma, pet meds, and natural and organic cosmetics.
Packaging > News

Contract Research & Services

AstraZeneca elects to return AZD9412 drug rights to Synairgen
By PBR Staff Writer
AstraZeneca has opted to return rights on drug AZD9412 (inhaled interferon beta) to Synairgen, which did not meet the pharma giant's predefined criteria for progression in a trial.
Contract Research & Services > Clinical Trials > News
Akebia expands anemia drug collaboration with Otsuka
By PBR Staff Writer
US-based Akebia Therapeutics has expanded its collaboration with Japan's Otsuka Pharmaceutical on an anemia treatment.
Contract Research & Services > Contract Services > News

Automation

Accenture, BioCelerate partner to advance biopharmaceutical innovation
Accenture and TransCelerate BioPharma's subsidiary BioCelerate have partnered to advance biopharmaceutical innovation through increased insights in research & development.
Automation > IT & Software > News
IBM scientists secure patent on machine learning models for drug discovery
By PBR Staff Writer
Technology giant IBM has secured a patent on machine learning models for drug discovery.
Automation > IT & Software > News

Regulatory Affairs

Shire wins EC conditional approval for Natpar to treat hypoparathyroidism
By PBR Staff Writer
Shire has secured conditional marketing approval from the European Commission (EC) for its Natpar (rhPTH[1-84]) to treat patients with chronic hypoparathyroidism.
Regulatory Affairs > News
EC approves AstraZeneca’s Tagrisso to treat mutation-positive NSCLC
By PBR Staff Writer
AstraZeneca has secured full marketing authorization from the European Commission (EC) for its Tagrisso (osimertinib) 40mg and 80mg once-daily tablets to treat adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
Regulatory Affairs > News



Data-Label.co.uk DataLabel have been supplying
the medical industry with labels
for over 10 years

Manufactures of
healthcare packaging
machinery